Duopharma Biotech Return On Equity vs. Z Score

7148 Stock   1.25  0.01  0.81%   
Considering the key profitability indicators obtained from Duopharma Biotech's historical financial statements, Duopharma Biotech Bhd may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Duopharma Biotech's ability to earn profits and add value for shareholders.
For Duopharma Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Duopharma Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Duopharma Biotech Bhd utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Duopharma Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Duopharma Biotech Bhd over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Duopharma Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Duopharma Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Duopharma Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Duopharma Biotech Bhd Z Score vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Duopharma Biotech's current stock value. Our valuation model uses many indicators to compare Duopharma Biotech value to that of its competitors to determine the firm's financial worth.
Duopharma Biotech Bhd is number one stock in return on equity category among its peers. It also is number one stock in z score category among its peers totaling about  0.27  of Z Score per Return On Equity. The ratio of Return On Equity to Z Score for Duopharma Biotech Bhd is roughly  3.64 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Duopharma Biotech's earnings, one of the primary drivers of an investment's value.

Duopharma Z Score vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Duopharma Biotech

Return On Equity

 = 

Net Income

Total Equity

 = 
10.93
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Duopharma Biotech

Z Score

 = 

Sum Of

5 Factors

 = 
3.0
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Duopharma Z Score Comparison

Duopharma Biotech is currently under evaluation in z score category among its peers.

Duopharma Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Duopharma Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Duopharma Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Duopharma Biotech's important profitability drivers and their relationship over time.

Use Duopharma Biotech in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Duopharma Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Duopharma Biotech will appreciate offsetting losses from the drop in the long position's value.

Duopharma Biotech Pair Trading

Duopharma Biotech Bhd Pair Trading Analysis

The ability to find closely correlated positions to Duopharma Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Duopharma Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Duopharma Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Duopharma Biotech Bhd to buy it.
The correlation of Duopharma Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Duopharma Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Duopharma Biotech Bhd moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Duopharma Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Duopharma Biotech position

In addition to having Duopharma Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Business Services Thematic Idea Now

Business Services
Business Services Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Business Services theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Business Services Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Duopharma Stock

To fully project Duopharma Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Duopharma Biotech Bhd at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Duopharma Biotech's income statement, its balance sheet, and the statement of cash flows.
Potential Duopharma Biotech investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Duopharma Biotech investors may work on each financial statement separately, they are all related. The changes in Duopharma Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Duopharma Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.